Rezolute, Inc. (RZLT)

CIK 0001509261 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q3-2026 8-K (2026-05-12) · 99.1
Q2-2026 8-K (2026-02-12) · 99.1
Q1-2026 8-K (2025-11-06) · 99.1
Latest FY-2025 8-K (2025-09-17) · 99.1
Q3-2025 8-K (2025-05-13) · 99.1
Q2-2025 8-K (2025-02-12) · 99.1
Q1-2025 8-K (2024-11-07) · 99.1
FY-2024 8-K (2024-09-19) · 99.1
Q3-2024 8-K (2024-05-15) · 99.1
Q2-2024 8-K (2024-02-13) · 99.1
Q1-2024 8-K (2023-11-13) · 99.1
FY-2023 8-K (2023-09-14) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Unaudited Condensed Consolidated Balance Sheets
—
Consolidated Balance Sheets (P)
Unaudited Condensed Consolidated Balance Sheets (P)
—
Consolidated Statements of Operations and Comprehensive Loss
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
—
Consolidated Statements of Shareholders' Equity
Unaudited Condensed Consolidated Statements of Shareholders' Equity
—
Consolidated Statements of Cash Flows
Unaudited Condensed Consolidated Statements of Cash Flows
—
Notes
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Derivative Liability For Authorized Share Deficiencies
—
Embedded Derivative Liability
Financial Instruments and Significant Concentrations
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Investments In Marketable Debt Securities
Leases
—
License Agreements
Liquidity
Nature of Operations and Summary of Significant Accounting Policies
Net Loss Per Share
Operating Leases
—
Pay Vs Performance Disclosure
Reduction In Workforce
—
Related Party Transactions
Segment Disclosures
Share-based Compensation and Warrants
Shareholders' Equity
Subsequent Events
Supplemental Financial Information
—